Biogen’s Tau-Targeting Therapy Shows Greater Slowing of Alzheimer’s Decline After Two Years

By Dr. Zubair Khalid, DVM, MS, PhD ·

Biogen’s Tau-Targeting Therapy Shows Greater Slowing of Alzheimer’s Decline After Two Years

Biogen reported that its tau-targeting antisense oligonucleotide continued to slow clinical decline in Alzheimer’s disease patients over a two-year period. The updated results, which analysts described as strengthening the case for late-stage development, showed a larger benefit than earlier data had indicated.

The therapy is designed to reduce production of tau protein, a key driver of neurodegeneration in Alzheimer’s. The new findings come from an ongoing clinical program and add to evidence that targeting tau may modify the course of the disease.

Context for the life sciences: Antisense oligonucleotides represent a precision approach to treating neurodegenerative diseases by directly interfering with the production of disease-related proteins. Tau pathology is a hallmark of Alzheimer’s and other tauopathies, making it a high-priority target. Positive long-term data from Biogen’s program could encourage further investment in RNA-based therapies for brain disorders and expand the toolkit for tackling conditions that currently have limited treatment options.

Source: original report

Related articles